Proteostasis Therapeutics, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Proteostasis Therapeutics, Inc. (“PTI” or the “Company”) (NASDAQ: PTI) in connection with the Company’s proposed merger with Yumanity Therapeutics, Inc. (“Yumanity”), a pharmaceutical company engaged in the development of treatment and disease modification for Parkinson’s disease. Under the terms of the merger agreement, which is structured as a reverse merger, PTI will acquire all outstanding shares of Yumanity in exchange for newly-issued shares of PTI common stock. At close of the transaction, PTI will cease to exist and the newly combined entity will operate under the Yumanity name. Following consummation, existing PTI shareholders will own a meager 32.5% of the new entity, with Yumanity shareholders retaining a 67.5% stake in the combined company.

WeissLaw is investigating whether PTI’s board satisfied its fiduciary duties to its shareholders by conducting a fair and diligent process, agreeing to an equity split that provides fair value to PTI shareholders, and whether all information regarding the process leading to the proposed transaction and valuation of the deal will be fully and fairly disclosed to PTI shareholders. These issues are of particular concern in light of the fact that existing PTI shareholders will only retain a 32.5% ownership of the combined company.\n\nWeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

Other Cases

April 12, 2021

Mackinac Financial Corporation Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Mackinac Financial Corporation (“Mackinac” or the “Company”) (NASDAQ: MFNC) in connection with the proposed acquisition of the Company by Nicolet Bankshares, Inc. (“Nicolet”) (NASDAQ: NCBS). Under the terms of the merger agreement, Mackinac shareholders will receive $4.64 in cash and 0.22 shares of Nicolet common stock for each Mackinac share that they own, representing implied consideration of $23.25 based upon Nicolet’s April 12, 2021 closing price of $84.60. The transaction is valued at approximately $248 million.

Join Case →

April 12, 2021

Nuance Communications, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Nuance Communications, Inc. (“Nuance” or the “Company”) (NASDAQ; NUAN) in connection with the proposed merger acquisition of the Company by Microsoft Corporation (“Microsoft”) (NASDAQ; MSFT). Under the terms of the merger agreement, the Company’s shareholders will receive only $56.00 per share in cash for each share of Nuance common stock that they hold. The all-cash transaction is valued at $19.7 billion.

Join Case →

April 12, 2021

Cadence Bancorporation Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cadence Bancorporation (“Cadence” or the “Company”) (NYSE: CADE) in connection with the proposed acquisition of the Company by BancorpSouth Bank (“BXS”) (NYSE: BXS). Under the terms of the merger agreement, Cadence shareholders will receive 0.70 shares of BXS common stock for each Cadence share that they own. Additionally, the agreement allows for a one-time special cash dividend to Cadence shareholders of $1.25 per share in conjunction with the closing of the merger. BXS shareholders will own approximately 55% and Cadence shareholders will own approximately 45% of the combined entity.

Join Case →